Abstracts tagged "Outcome measures"

Abstract Number: 0690 • ACR Convergence 2021
Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
Didem Saygin¹, Siamak Moghadam-Kia², Chester Oddis², Dana Ascherman², Nicole Neiman², Diane Koontz² and Rohit Aggarwal², ¹University of Chicago, Chicago, IL, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The 2016 ACR/EULAR Myositis Response Criteria represent a composite measure that is increasingly being used as a primary end point in myositis clinical trials.…
Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Panagiotis Athanassiou¹, Andreas Bounas², Dimitrios Boumpas³, Prodromos Sidiropoulos⁴, Christina Tsalapaki⁵, Alexandros Garyfallos⁶, Eleftheria Grika⁷, Paraskevi Voulgari⁸, Angeliki Kekki⁹, Zafeirios Anagnostopoulos⁹, Georgios Karachalios⁹ and Nikos Antonakopoulos⁹, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ³“Attikon” University Hospital, Rheumatology and Clinical Immunology Unit ,4th University Pathology Clinic, Athens, Greece, ⁴Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁵General Hospital of Athens “Hippokratio", Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁶General Hospital of Thessaloniki “Ippokratio" , Τhessaloniki, Greece, Thessaloniki, Greece, ⁷Rheumatology Clinic, General Hospital “Evangelismos”, Athens, Greece, ⁸Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁹Genesis Pharma SA, Athens, Greece, Athens, Greece
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…
Abstract Number: 1261 • ACR Convergence 2021
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Sharzad Emamikia¹, Shereen Oon², Alvaro Gomez¹, Julius Lindblom¹, Alexander Borg¹, Yvonne Enman¹, Eric Morand³, David Grannas⁴, Ronald van Vollenhoven⁵, Mandana Nikpour⁶ and Ioannis Parodis⁷, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Department of Rheumatology, St Vincent's Hospital, Fitzroy, Australia, ³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ⁴Divison of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Background/Purpose: Health-related quality of life (HRQoL) is considered one of the most important outcomes in clinical trials of systemic lupus erythematosus (SLE), along with reduction…
Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Elisheva Pokroy-Shapira¹, Iftach Sagy², Katya Meridor³ and Yair Molad⁴, ¹Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, ²Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ³Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ⁴Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
Abstract Number: 0341 • ACR Convergence 2021
Addition of Narrative Text Abstraction to ICD-Based Abstraction Significantly Improves Identification of Lupus Nephritis in Real-World Data
Meghan Tierney and Chris Rowe, PicnicHealth, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is often underrecognized and difficult to identify retrospectively, presenting challenges for clinicians and researchers hoping to explore this condition using real-world…
Abstract Number: 0717 • ACR Convergence 2021
Association of Fatigue with Disease Activity in Myositis
Tissa Bijoy George¹, Anjana Chandrasekhara Pillai², Siamak Moghadam-Kia³, Nicole Neiman⁴, Dana Ascherman³, Chester Oddis³, Dianxu Ren⁴ and Rohit Aggarwal³, ¹UPMC McKeesport, Monroeville, PA, ²UPMC, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The Idiopathic inflammatory myopathies are a heterogeneous group of rare systemic autoimmune diseases with muscle as the primary target. Fatigue is one of the…
Abstract Number: 0850 • ACR Convergence 2021
Regression Methods for Modeling Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Scores for Early Stage Knee Osteoarthritis
Benjamin Sweigart and Michael LaValley, Boston University School of Public Health, Boston, MA
Background/Purpose: The Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score [range 0-20] is a common outcome measure for clinical trials and observational studies…
Abstract Number: 1268 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
Melissa Fazzari¹, Marta Guerra², Jane Salmon² and Mimi Kim³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in patients with Systemic lupus erythematosus (SLE) result in an adverse pregnancy outcome (APO); early identification of women with SLE…
Abstract Number: 1893 • ACR Convergence 2021
“From Where I Stand”: Using Multiple Anchors Yields Different Benchmarks for Meaningful Improvement and Worsening in the Rheumatoid Arthritis Flare Questionnaire (RA-FQ)
Susan Bartlett¹, Vivian Bykerk², Orit Schieir³, Marie-France Valois¹, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹, Clifton Bingham¹² and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Hospital for Special Surgery, New York, NY, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: The RA-FQ is a patient-reported measure of current disease activity in RA that can be used to identify disease flares. The RA-FQ queries pain,…
Abstract Number: 0362 • ACR Convergence 2021
Achievement of Stringent Thresholds of Disease Control Is Associated with Reduced Burden on Work and Household Productivity in Patients with Axial Spondyloarthritis
Martin Rudwaleit¹, Pedro Machado², Lianne Gensler³, Vanessa Taieb⁴, Natasha de Peyrecave⁵, Bengt Hoepken⁶ and Désirée van der Heijde⁷, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with increased absence from work and reduced work productivity, which can impact employment status.1 TNF inhibitors such as certolizumab…
Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 0864 • ACR Convergence 2021
Does Obesity Affect Disease Activity Outcomes in Systemic Lupus Erythematosus?
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Hamilton, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada
Background/Purpose: Increased Body Mass Index (BMI) affects cardiovascular risk and is related to worse health-related quality of life measures in patients with systemic lupus erythematosus…
Abstract Number: 1276 • ACR Convergence 2021
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
Manuel Ugarte-Gil¹, Guillermo Ruiz-Irastorza², Dafna Gladman³, Murray Urowitz⁴, Ann Clarke⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Sasha Bernatsky¹¹, Daniel Wallace¹², David Isenberg¹³, Anisur Rahman¹⁴, Joan Merrill¹⁵, Paul R Fortin¹⁶, Ian N. Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jnsen²³, Ronald F van Vollenhoven²⁴, Cynthia Aranow²⁵, Meggan Mackay²⁵, S Sam Lim²⁶, Murat Inanc²⁷, Kenneth Kalunian²⁸, Soren Jacobsen²⁹, Christine Peschken³⁰, Diane Kamen³¹, Anca Askanase³², Bernardo A. Pons-Estel³³ and Graciela Alarcn³⁴, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, Republic of Korea, ⁹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, ¹⁰Instituto Nacional de Ciencias Médicas y Nutrición, Inmunología y Reumatología, Mexico City, Mexico, ¹¹McGill University, Montréal, QC, Canada, ¹²Cedars-Sinai, Los Angeles, CA, ¹³Centre for Rheumatology, University College London, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁷University of Manchester, Manchester, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, Brooklyn, NY, ²⁰Raleigh Neurology Associates, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Wexford, PA, ²³Lund University, Lund, Sweden, ²⁴Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²⁵Feinstein Institutes for Medical Research, Manhasset, NY, ²⁶Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ²⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ²⁸UC San Diego, La Jolla, CA, ²⁹Rigshospitalet, Copenhagen, Denmark, ³⁰University of Manitoba, Winnipeg, MB, Canada, ³¹Medical University of South Carolina, Charleston, SC, ³²Columbia University Medical Center, New York, NY, ³³Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina, ³⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remission and LLDAS have been proposed as the goals for the treatment of SLE patients. However, the predictors of each state remain unknown. The…
Abstract Number: 1910 • ACR Convergence 2021
Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial
Laure Gossec¹, Nemanja Damjanov², Shigeyoshi Tsuji³, Apinya Lertratanakul⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, Patrick Zueger⁶ and Kurt de Vlam⁷, ¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²University of Belgrade School of Medicine, Institute of Rheumatology, Belgrade, Serbia, ³Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷Department of Rheumatology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Background/Purpose: The achievement of disease control has been shown to be associated with improved prognosis in PsA, though no single measure of low disease activity…
Abstract Number: 0391 • ACR Convergence 2021
High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time
Elizabeth Marjanovic¹, Calvin Heal¹, Tonia Moore¹, Joanne Manning², Sarah Wilkinson¹, Graham Dinsdale², Mark Dickinson¹, Jack Wilkinson¹, Ariane Herrick³ and Andrea Murray¹, ¹University of Manchester, Manchester, United Kingdom, ²Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ³University of Manchester, Salford, United Kingdom
Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].